APTAMER GROUP PLC — Share Issue/Capital Change 2025

Feb 25, 2025

National Storage Mechanism | Additional information

RNS Number : 2691Y

Aptamer Group PLC

25 February 2025

25 February 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Block Listing Interim Review

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:

Name of Company	Aptamer Group plc
Name of Scheme	The Aptamer Group EMI Share Option Scheme
Period of Return (from/to)	25 August 2024 to 24 February 2025
Number and class of securities not issued at the start of the period under the scheme	1,666,477 Ordinary Shares
Number of securities issued under the scheme during the period	0
Number of securities lapsed/waived under the scheme during the period	1,090,424 Ordinary Shares
Balance under the scheme of securities not yet issued at the end of the period	576,053 Ordinary Shares
Number and class of securities originally admitted and the date of admission	2,063,200 Ordinary Shares on 25 February 2022
Name of contact and telephone number	Andrew Rapson +44 (0) 1904 217 404

- Ends -

For further information, please contact: 

Aptamer Group plc    Arron Tolley, Chief Executive Officer	+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser      Andrew Emmott / Jade Bayat	+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker      James Pope / Andrew Thacker	+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations Sarah Hollins	+44 (0) 113 730 3896

About Aptamer Group plc  

Aptamer Group is a leading global developer of aptamer-based ligands that help scientists remove the limits to discovery and innovation. Leveraging several proprietary discovery and development platform, Aptamer delivers custom affinity ligands, supported with a complete suite of characterisation and validatory assays that enhance the translation of its binders and optimise scientific outcomes for customers.

Aptamer's cutting-edge technology spans healthcare, research, personal care, and industrial processes, delivering new affinity solutions for novel targets, advanced diagnostics, and precision therapies. By working with industry leaders in pharmaceutical, biotechnology, personal health, academic, and clinical research sectors, Aptamer is accelerating science through the custom development of tools and therapies.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRDZLFLELLLBBV